

# Merseyside Inter Agency Drug Misuse Database

**Knowsley DAAT** 

Quarter 4 2007/08

Lloyd Baron, Martin Chandler, Jim McVeigh

www.cph.org.uk/iad

#### Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Paul Duffy, Adam Marr, Simon Russell and Claire Shaw.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531 m.chandler@ljmu.ac.uk

Lloyd Baron IAD Researcher

(0151) 231 4521 L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

# Contents

Introduction		P <u>age</u> 1
Arrest Referral		3
	Table 1: Individuals assessed, by Gender	
	and Age Group	
	Table 2: Year to Date, by Gender and Age Group	
	Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Syringe Exchange	e Services	5
Agend		
J	Table 4: Individuals by Gender	
	Table 5: Individuals by Gender: Steroid Users omitted	
	Table 6: Individuals by Age Group	
	Table 7: Individuals by Age Group: Steroid Users omitted	
	Table 8: Gender by Age Group of Individuals	
	Table 9: Gender by Age Group: Steroid Users omitted	
	Table 10: Year to Date, by Gender & Age Group	
	Table 11: Year to Date, by Gender & Age Group: Steroid Users omitted	3
	Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	<b>;</b>
	Table 13: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	Э
Pharn		10
	Table 14: Individuals by Gender	
	Table 15: Individuals by Age Group	
	Table 16: Year to Date, by Gender & Age Group	
Comb	ined	11
	Table 17: Individuals in Syringe Exchange, by Gender	
	Table 18: Individuals in Syringe Exchange, by Gender: Steroid omitted	Users
	Table 19: Individuals in Syringe Exchange, by Age Group	
	Table 20: Individuals in Syringe Exchange, by Age Group: Stere Users omitted	oid
	Table 21: Year to Date, by Gender & Age Group	
	Table 22: Total Syringes Provided	

<b>National Drug Trea</b>	atment Monitoring System (NDTMS)	13
	Table 23: Individuals in contact with Treatment Services, by Gende	er
	Table 24: Year to Date, by Gender	
	Table 25: Individuals in contact with Treatment Services, by Age	
	Group	
	Table 26: Year to Date, by Age Group	
	Table 27: Ethnicity of Individuals in Contact with Treatment Service	es
	Table 28: Individuals in contact with Treatment Services, by Main	
	Drug of Use	
Connexions		16
o o mio xio no	Table 29: Individuals in Contact with Connexions, by Gender	. •
	Table 30: Year to Date, by Gender	
	Table 31: Individuals in Contact with Connexions, by Age	
	Table 32: Year to Date, by Age	
	Table 33: Individuals in Contact with Connexions by Drug/Alcohol	
	Problem	
	Table 34: Year to Date, by Drug/Alcohol Problem	
Combined Dataset	:S	18
	Table 35: Total Problem Drug Users reported to the IAD, by	
	Gender and Age Group	
	Table 36: Year to Date, by Gender & Age Group	
Cross Matched Da	tasets	19
	Fig 1: Crossover between Agency Syringe Exchange	
	and NDTMS datasets	
	Fig 2: Crossover between Pharmacy Syringe Exchange and	
	NDTMS datasets	

#### Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

#### **Data considerations**

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

# ARREST REFERRAL (AR)

Quarter 4 (2007/08)

#### Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	62	86.1
Female	10	13.9
Age Group		
Under 18	0	0.0
18-19	7	9.7
20-24	17	23.6
25-29	20	27.8
30-34	11	15.3
35-39	10	13.9
40-44	4	5.6
45+	3	4.2
Total	72	100

Table 2: Year to Date, by Gender & Age Group

		Ger	nder			
	M	ale	Fen	nale	Total in A	lge Group
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	23	10.4	1	3.0	24	9.4
20-24	49	22.2	5	15.2	54	21.3
25-29	52	23.5	8	24.2	60	23.6
30-34	35	15.8	6	18.2	41	16.1
35-39	29	13.1	4	12.1	33	13.0
40-44	18	8.1	7	21.2	25	9.8
45+	15	6.8	2	6.1	17	6.7
Total	221	100	33	100	254	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	0	0
Benzodiazepines	1	0
Cannabis	8	1
Crack	15	6
Cocaine	5	15
Ecstasy	0	0
Heroin	21	1
Methadone	9	1

**NB:** The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

# **SYRINGE EXCHANGE SERVICES**

Quarter 4 (2007/08)

# Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

# **AGENCY SYRINGE EXCHANGE**

Table 4: Individuals by Gender

New Clients	n	%
Male	74	97.4
Female	2	2.6
Total	76	100
All Clients		
Male	138	95.2
Female	7	4.8
Total	145	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	28	93.3
Female	2	6.7
Total	30	100
All Clients		
Male	73	91.3
Female	7	8.8
Total	80	100

Table 6: Individuals by Age Group

	New	Clients	All C	lients
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	11	14.5	12	8.3
20-24	17	22.4	23	15.9
25-29	11	14.5	22	15.2
30-34	15	19.7	30	20.7
35-39	10	13.2	32	22.1
40-44	7	9.2	17	11.7
45+	5	6.6	9	6.2
Total	76	100	145	100

Table 7: Individuals by Age Group: Steroid Users omitted

	New	Clients	All C	lients
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	6.7	2	2.5
20-24	3	10.0	4	5.0
25-29	5	16.7	9	11.3
30-34	7	23.3	21	26.3
35-39	6	20.0	25	31.3
40-44	4	13.3	13	16.3
45+	3	10.0	6	7.5
Total	30	100	80	100

Table 8: Gender by Age Group of Individuals

		Ge	nder	
	М	ale	Fei	male
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	12	8.7	0	0.0
20-24	22	15.9	1	14.3
25-29	22	15.9	0	0.0
30-34	28	20.3	2	28.6
35-39	31	22.5	1	14.3
40-44	15	10.9	2	28.6
45+	8	5.8	1	14.3
Total	138	100	7	100

Table 9: Gender by Age Group: Steroid Users omitted

		Ge	nder	
	M	lale	Fe	male
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	2.7	0	0.0
20-24	3	4.1	1	14.3
25-29	9	12.3	0	0.0
30-34	19	26.0	2	28.6
35-39	24	32.9	1	14.3
40-44	11	15.1	2	28.6
45+	5	6.8	1	14.3
Total	73	100	7	100

Table 10: Year to Date, by Gender & Age Group

		Ger	nder			
	M	ale	Fen	nale	Total in A	lge Group
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	27	6.5	0	0.0	27	6.1
20-24	68	16.3	2	7.4	70	15.7
25-29	105	25.1	4	14.8	109	24.5
30-34	74	17.7	7	25.9	81	18.2
35-39	81	19.4	8	29.6	89	20.0
40-44	41	9.8	4	14.8	45	10.1
45+	22	5.3	2	7.4	24	5.4
Total	418	100	27	100	445	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

		Gei				
	M	ale	Fen	nale	Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	2	1.0	0	0.0	2	<1
20-24	13	6.7	2	7.7	15	6.8
25-29	39	20.0	4	15.4	43	19.5
30-34	38	19.5	6	23.1	44	19.9
35-39	57	29.2	8	30.8	65	29.4
40-44	32	16.4	4	15.4	36	16.3
45+	14	7.2	2	7.7	16	7.2
Total	195	100	26	100	221	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

	Gender						
	P	Male	Fen	nale			
Drug of Use	n	%	n	%			
Amphetamines	0	0.0	0	0.0			
Benzodiazepines	0	0.0	0	0.0			
Cocaine	0	0.0	0	0.0			
Crack	0	0.0	0	0.0			
Heroin	9	12.2	1	50.0			
Methadone	1	1.4	0	0.0			
Steroids	46	62.2	0	0.0			
Other	18	24.2	1	50.0			
Total	74	100	2	100			

**Please Note:** Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 13: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

	<u> </u>	heta- ne	医医医医医医医	zodi- pine	Coc	aine	Cra	ack	He	roin	Metha	adone	Ster	oids
Age Group	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18-19	-	-	-	-	-	-	-	-	-	-	-	-	9	20.0
20-24	-	-	-	-	-	-	-	-	-	-	-	-	14	30.0
25-29	-	-	-	-	-	-	-	-	-	-	-	-	6	14.0
30-34	-	-	-	-	-	-	-	-	4	40.0	-	-	8	16.0
35-39	-	-	•	-	-	-	-	-	1	10.0	1	100	4	9.0
40-44	-	-		-	-	-	-	-	3	30.0	-	-	3	7.0
45+	-	-	•	-	-	-	-	-	2	20.0	-	-	2	4.0
Total	-	-	-	-	-	-	-	-	10	100	1	100	46	100

<sup>\* %</sup> Totals are by Drug, not Age Group

# **PHARMACY SYRINGE EXCHANGE**

Table 14: Individuals by Gender

New Clients	n	%	
Male	0	0.0	
Female	1	100	
Total	1	100	
All Clients			
Male	1	33.3	
Female	2	66.7	
Total	3	100	

Table 15: Individuals by Age Group

	New	Clients	All Clients		
Age Group	n	%	n	%	
Under 18	0	0.0	0	0.0	
18-19	0	0.0	0	0.0	
20-24	1	100	1	33.3	
25-29	0	0.0	1	33.3	
30-34	0	0.0	0	0.0	
35-39	0	0.0	0	0.0	
40-44	0	0.0	1	33.3	
45+	0	0.0	0	0.0	
Total	1	100	3	100	

Table 16: Year to Date, by Gender & Age Group

		Ger	nder			
	M	Male		nale	Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	2.6	1	8.3	2	3.9
20-24	6	15.4	3	25.0	9	17.6
25-29	13	33.3	4	33.3	17	33.3
30-34	8	20.5	3	25.0	11	21.6
35-39	6	15.4	1	8.3	7	13.7
40-44	4	10.3	0	0.0	4	7.8
45+	1	2.6	0	0.0	1	2.0
Total	39	100	12	100	51	100

# **COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE**

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 17: Individuals in Syringe Exchange, by Gender

New Clients	n	%	
Male	74	96.1	
Female	3	3.9	
Total	77	100	
All Clients			
Male	139	93.9	
Female	9	6.1	
Total	148	100	

Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted

New Clients	n	%
Male	28	90.3
Female	3	9.7
Total	31	100
All Clients		
Male	74	89.2
Female	9	10.8
Total	83	100

Table 19: Individuals in Syringe Exchange, by Age Group

	New	Clients	All Clients		
Age Group	n	%	n	%	
Under 18	0	0.0	0	0.0	
18-19	11	14.3	12	8.1	
20-24	18	23.4	24	16.2	
25-29	11	14.3	23	15.5	
30-34	15	19.5	30	20.3	
35-39	10	13.0	32	21.6	
40-44	7	9.1	18	12.2	
45+	5	6.5	9	6.1	
Total	77	100	148	100	

Table 20: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

	New	Clients	All Clients		
Age Group	n	%	n	%	
Under 18	0	0.0	0	0.0	
18-19	2	6.5	2	2.4	
20-24	4	12.9	5	6.0	
25-29	5	16.1	10	12.0	
30-34	7	22.6	21	25.3	
35-39	6	19.4	25	30.1	
40-44	4	12.9	14	16.9	
45+	3	9.7	6	7.2	
Total	31	100	83	100	

Table 21: Year to Date, by Gender & Age Group

		Ger				
	Male		Fen	nale	Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	28	6.2	1	2.6	29	5.9
20-24	74	16.3	5	12.8	79	16.0
25-29	117	25.8	8	20.5	125	25.4
30-34	82	18.1	10	25.6	92	18.7
35-39	87	19.2	9	23.1	96	19.5
40-44	43	9.5	4	10.3	47	9.5
45+	23	5.1	2	5.1	25	5.1
Total	454	100	39	100	493	100

**Table 22: Total Syringes Provided** 

	Agency	Pharmacy	Total (Q)	YTD
Barrels	6,339	3,448	9,787	31,323

**NB:** We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

# **National Drug Treatment Monitoring System (NDTMS)**

Quarter 4 (2007/08)

# **Background**

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

#### **New Clients**

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 23: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	127	72.2
Female	49	27.8
Total	176	100
All Clients		
Male	1166	72.2
Female	450	27.8
Total	1616	100

Table 24: Year to Date, by Gender

New Clients	n	%
Male	457	70.5
Female	191	29.5
Total	648	100
All Clients		
Male	1315	73.0
Female	487	27.0
Total	1802	100

Table 25: Individuals in Contact with Treatment Services, by Age Group

	New	Clients	All C	lients
Age Group	n	%	n	%
Under 18	26	14.7	193	11.9
18-19	6	3.4	36	2.2
20-24	27	15.3	146	9.0
25-29	20	11.3	176	10.8
30-34	25	14.2	257	15.9
35-39	30	17.0	372	23.0
40-44	29	16.4	286	17.7
45+	13	7.3	150	9.2
Total	176	100	1616	100

Table 26: Year to Date, by Age Group

	New Clients		All C	lients
Age Group	n	%	n	%
Under 18	111	17.1	215	11.9
18-19	21	3.2	64	3.6
20-24	72	11.1	225	12.5
25-29	76	11.7	246	13.7
30-34	109	16.8	336	18.6
35-39	106	16.4	344	19.1
40-44	101	15.6	248	13.8
45+	52	8.0	124	6.9
Total	648	100	1802	100

Table 27: Ethnicity of Individuals in Contact with Treatment Services

	New	Clients	All C	lients
Ethnicity	n	%	n	%
White British	171	97.1	1572	98.2
White Irish	0	0.0	3	>1
Other White	1	>1	3	>1
White & Black Caribbean	1	>1	5	>1
White & Black African	1	>1	3	>1
White & Asian	0	0.0	1	>1
Other Mixed	0	0.0	2	>1
Other Asian	0	0.0	1	>1
African	0	0.0	1	>1
Other Black	0	0.0	5	>1
Chinese	1	>1	1	>1
Other	1	>1	3	>1
Unknown	0	0.0	16	>1
Total	176	100	1616	100

Table 28: Individuals in Contact with Treatment Services, by Main Drug of Use

	New (	Clients	All C	lients
Drug of Use	n	%	n	%
Heroin	57	32.3	809	50.06
Methadone	14	7.9	56	3.4
Other Opiates	4	2.2	14	>1
Benzodiazepine	0	0.0	6	>1
Amphetamines	6	3.4	40	2.4
Cocaine	42	23.8	223	13.8
Crack	7	3.9	38	2.3
Ecstasy	2	1.1	13	>1
Cannabis	43	24.4	408	25.2
Other/Unknown	1	>1	9	>1
Total	176	100	1616	100

# **CONNEXIONS**

Quarter 4 (2007/08)

# **Background**

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 29: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	20	51.3
Female	19	48.7
Total	39	100

Table 30: Year to Date, by Gender

Gender	n	%
Male	37	59.7
Female	25	40.3
Total	62	100

Table 31: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	7	17.9
17	13	33.3
18	13	33.3
19	6	15.4
Total	39	100

Table 32: Year to Date, by Age

Age Group	n	%
16	10	16.1
17	17	27.4
18	18	29.0
19	17	27.4
Total	62	100

Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	12	30.8
Drugs	27	69.2
Total	39	100

<sup>\*&</sup>quot;Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 34: Year to Date, by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	17	27.4
Drugs	45	72.6
Total	62	100

<sup>\*&</sup>quot;Other" is generally used to refer to solvents although this is not necessarily always the case.

# **COMBINED DATASETS**

Quarter 4 (2007/08)

#### Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%	
Male	1342	73.9	
Female	475	26.1	
Age Group			
Under 18	223	12.3	
18-19	90	5.0	
20-24	225	12.4	
25-29	263	14.5	
30-34	322	17.7	
35-39	341	18.8	
40-44	233	12.8	
45+	120	6.6	
Total	1817	100	

Table 36: Year to Date, by Gender and Age Group

Age Group		Gender				
	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	122	6.3	99	17.6	221	8.8
18-19	109	5.6	21	3.7	130	5.2
20-24	289	14.9	37	6.6	326	13.0
25-29	301	15.5	91	16.2	392	15.6
30-34	303	15.6	89	15.9	392	15.6
35-39	383	19.7	109	19.4	492	19.6
40-44	289	14.9	76	13.5	365	14.6
45+	149	7.7	39	7.0	188	7.5
Total	1945	100	561	100	2506	100

# **CROSS-MATCHED DATASETS**

Quarter 4 (2007/08)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets




Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets datasets

